<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dermatol Ther (Heidelb)</journal-id><journal-id journal-id-type="iso-abbrev">Dermatol Ther (Heidelb)</journal-id><journal-title-group><journal-title>Dermatology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8210</issn><issn pub-type="epub">2190-9172</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6380980</article-id><article-id pub-id-type="publisher-id">275</article-id><article-id pub-id-type="doi">10.1007/s13555-018-0275-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><italic>Propionibacterium</italic> (<italic>Cutibacterium</italic>) <italic>acnes</italic> Bacteriophage Therapy in Acne: Current Evidence and Future Perspectives</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Castillo</surname><given-names>David E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nanda</surname><given-names>Sonali</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Keri</surname><given-names>Jonette E.</given-names></name><address><email>jkeri@med.miami.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8606</institution-id><institution-id institution-id-type="GRID">grid.26790.3a</institution-id><institution>Department of Dermatology and Cutaneous Surgery, </institution><institution>University of Miami Miller School of Medicine, </institution></institution-wrap>Miami, FL USA </aff><aff id="Aff2"><label>2</label>Veterans Affairs Miami Health Care System, Miami, FL USA </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>12</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>12</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2019</year></pub-date><volume>9</volume><issue>1</issue><fpage>19</fpage><lpage>31</lpage><history><date date-type="received"><day>14</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement></permissions><abstract id="Abs1"><p id="Par1">Acne vulgaris is the most common dermatological disorder worldwide. It is a multifactorial disease that involves increased sebum production, hyperkeratinization of the pilosebaceous unit, <italic>Propionibacterium acnes</italic> (<italic>Cutibacterium acnes</italic>) colonization, and inflammation. The human skin microbiome hosts a wide variety of microorganisms, including bacteria, viruses, and fungi. A delicate balance of these microorganisms is essential for the barrier function of the skin. <italic>Propionibacterium acnes</italic> represents nearly 90% of the human skin microbiome of healthy adults. Acne is a chronic recurrent disease that requires long-lasting treatment, which has led to the emergence of antibiotic resistance. New alternatives to traditional therapy are emerging, including antimicrobial peptides, natural engineered antibodies, and bacteriophages. Bacteriophages have been shown to play a role in human skin health and disease. There is evidence supporting phage therapy in many types of skin infections. <italic>P. acnes</italic> bacteriophages have been isolated and characterized. However, only a few in vitro studies have tested the ability of bacteriophages to kill <italic>P. acnes</italic>. Furthermore, there is no evidence on bacteriophage therapy in the treatment of acne in humans. In this review, we summarize the most recent evidence regarding <italic>P. acnes</italic> bacteriophages and the potential role of these bacteriophages in the treatment of acne. Further research on this field will provide the evidence to use phage therapy to decrease rates of antibiotic resistance and restore antibiotic susceptibility of <italic>P. acnes</italic>.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Acne</kwd><kwd>Antibiotic resistance</kwd><kwd>Bacteriophages</kwd><kwd>Microbiome</kwd><kwd>Phage therapy</kwd><kwd>Phages</kwd><kwd><italic>Propionibacterium acnes</italic></kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Acne vulgaris is the most common dermatological disorder worldwide. It affects around 50 million people each year in the USA, with an estimated annual cost of $2.5 billion [<xref ref-type="bibr" rid="CR1">1</xref>]. The worldwide prevalence of acne is estimated to be around 9% [<xref ref-type="bibr" rid="CR2">2</xref>], accounting for 0.3% of the global disease burden [<xref ref-type="bibr" rid="CR3">3</xref>]. Although acne affects people of all ages, 85% of all affected individuals are 12&#x02013;24&#x000a0;years old [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Severe acne also carries a high social and psychological impact, affecting emotions, self-esteem, and increasing the risk of depression and suicide [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par3">The role of <italic>Propionibacterium acnes</italic> in the pathophysiology of acne is still under debate. <italic>P. acnes</italic> is the predominant commensal microorganism of the human skin microbiome. A delicate balance within the skin microbiota is essential for the barrier function of the skin and prevention of pathogen colonization [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par4">The emergence of antibiotic resistance has become a public health problem worldwide [<xref ref-type="bibr" rid="CR9">9</xref>]. The long-term use of topical and systemic antibiotics has led to high rates of antibiotic-resistant <italic>P. acnes</italic> strains [<xref ref-type="bibr" rid="CR10">10</xref>]. As research on new antibiotic agents is decreasing due to cost and difficulty, the development of new, natural, and non-conventional alternatives&#x02014;such as antimicrobial peptides, natural engineered antibodies, and bacteriophages&#x02014;is becoming critical. Bacteriophage therapy seems to be a promising alternative. Its advantages are host specificity and simplicity of isolation and production. Although both in vitro and in vivo studies have shown the potential of targeted bacteriophage therapy in skin infections, research is lacking on bacteriophage therapy targeting <italic>P. acnes</italic>-associated infections. It has recently been proposed that the species <italic>P. acnes</italic> be reclassified to <italic>Cutibacterium acnes</italic> and other genera [<xref ref-type="bibr" rid="CR11">11</xref>]. Here, we use the old nomenclature (<italic>P. acnes</italic>) throughout because it is still used by most of the evidence presented in this review. In this review, we summarize the most recent evidence on <italic>P. acnes</italic> bacteriophages and its potential role in the treatment of acne. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.</p></sec><sec id="Sec2"><title>Acne Vulgaris Pathophysiology</title><p id="Par5">Acne is a multifactorial disease. Increased sebum production by androgen stimulation, abnormal hyperkeratinization of the pilosebaceous duct, and subsequent bacterial colonization and inflammation all contribute to the disease [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. It is proposed that <italic>P. acnes</italic> colonization plays a pivotal role in the pathogenesis of acne since antimicrobial therapy has been effective in treating acne for many years. However, its contribution to acne development is controversial [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par6"><italic>Propionibacterium acnes</italic> is a Gram-positive, anaerobic/microaerophilic, fat-splitting, rod-shaped bacterium found on the skin; it represents nearly 90% of the skin microbiome of healthy adults [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The concentration of <italic>P. acnes</italic> depends on the abundance of sebaceous follicles and the age of the individual [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Accordingly, its concentration is higher on sebaceous areas such as the face, scalp, and back [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], and various studies have reported an association between <italic>P. acnes</italic> levels and sebum production [<xref ref-type="bibr" rid="CR16">16</xref>]. There is a marked increase in <italic>P. acnes</italic> colonization during puberty [<xref ref-type="bibr" rid="CR15">15</xref>], which correlates with the time when sebaceous glands mature [<xref ref-type="bibr" rid="CR13">13</xref>]. <italic>P. acnes</italic> may disrupt keratinocyte differentiation in the follicle, thereby contributing to the formation of comedones and inflammatory acne lesions by triggering a host inflammatory response [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. <italic>P. acnes</italic> produces enzymes that degrade skin components as well as chemotactic factors that stimulate keratinocytes and inflammatory cells to release pro-inflammatory cytokines (e.g., interleukin [IL]-8, IL-12, IL-1&#x003b1;, IL1-&#x003b2;, tumor necrosis factor alpha) and reactive oxygen species [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Although <italic>P. acnes</italic> is a commensal organism in humans, not all healthy adolescents or adults develop acne, indicating that differences in the pathogenicity of <italic>P. acnes</italic> strains must exist [<xref ref-type="bibr" rid="CR1">1</xref>]. It has been proposed that certain strains play a pathogenic role and others act as bystanders [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Studies have also shown that specific genes in the <italic>P. acnes</italic> genome contribute to bacterium virulence and hence to acne pathophysiology [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec3"><title>Emerging Antibiotic Resistance</title><p id="Par7">Over 2 million Americans become infected every year with antibiotic-resistant bacteria, resulting in about 23,000 deaths [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The post-antibiotic era is approaching as antibiotic effectiveness steadily declines, and multiple common infections become resistant to treatment [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The excessive use of antibiotics in agriculture and humans, the evolutionary pressure inherent to antibiotics [<xref ref-type="bibr" rid="CR31">31</xref>], and the lack of research on new antibiotic agents are some of the reasons behind antibiotic resistance [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par8">Antibiotic resistance is among the main causes of treatment failure in acne vulgaris [<xref ref-type="bibr" rid="CR33">33</xref>]. The mechanism of antibiotic resistance to <italic>P. acnes</italic> is explained by the remarkable genetic plasticity of bacteria [<xref ref-type="bibr" rid="CR34">34</xref>]. Two major genetic strategies permit antimicrobial resistance: (1) gene mutation, and (2) foreign DNA coding acquisition through horizontal gene transfer [<xref ref-type="bibr" rid="CR34">34</xref>]. Gene mutation is the predominant mechanism leading to <italic>P. acnes</italic> antibiotic resistance [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par9">Acne therapy warrants long-term treatment with topical and systemic antibiotics, which contributes to resistant <italic>P. acnes</italic> strains. Globally, <italic>P. acnes</italic> resistance to antimicrobials has increased almost 40% between the 1980s and 2000s worldwide [<xref ref-type="bibr" rid="CR10">10</xref>]. Erythromycin/clindamycin-resistant <italic>P. acnes</italic> seems to be the most common pattern of resistance based on reports from the USA, Europe, and Asia [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>]. However, resistance rates vary by region. Europe, Singapore, and Hong-Kong have high prevalence rates of erythromycin/clindamycin-resistant <italic>P. acnes</italic> (45&#x02013;91%) and tetracycline-resistant <italic>P. acnes</italic> (2&#x02013;26%) [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>], but countries that practice conservative use of antibiotics, such as Japan and Korea, report much lower resistance rates (2&#x02013;4%) [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par10">The long-term use of antibiotics can promote the formation of an antibiotic-resistant biofilm that protects the bacterium against host defenses and can alter the natural microbiota of the skin [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Studies have shown colonization by antibiotic-resistant coagulase-negative <italic>Staphylococci</italic> and <italic>Streptococcus pyogenes</italic> in acne patients who have used both topical and oral antibiotic therapy [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Thereby, it is recommended to limit monotherapy with topical antibiotics and instead to combine them with other topical agents such as retinoids or benzoyl peroxide to decrease the risk of resistance [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="Sec4"><title>Human Skin Microbiome</title><p id="Par11">The human skin microbiome is home to a variety of microorganisms, including bacteria, fungi, viruses, and arthropods. A delicate balance between the microorganisms is essential for local immunity and barrier function of the skin [<xref ref-type="bibr" rid="CR8">8</xref>]. Imbalances in this system have been linked to dermatologic diseases, such as acne, atopic dermatitis, psoriasis, and rosacea [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par12">The dominant bacterial species found on adult skin are <italic>Propionibacterium</italic>, <italic>Corynebacterium</italic>, and <italic>Staphylococcus</italic> [<xref ref-type="bibr" rid="CR48">48</xref>]. The skin can be divided into dry, moist, or sebaceous microenvironments, and each of these microclimates host varying proportions of these common bacterial flora [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par13">Age-related shifts in bacterial communities could explain why certain skin diseases are prevalent at different stages of life. For example, the microbiome in children, who are more susceptible to atopic dermatitis, is composed of mostly <italic>Streptococcaceae</italic>, <italic>Bacteroides</italic>, and <italic>Proteobacteria</italic> [<xref ref-type="bibr" rid="CR49">49</xref>]. Pubertal spikes in androgens lead to a more susceptible environment for the development of acne and a shift in microbiome concentration to greater levels of <italic>Propionibacterium</italic> and <italic>Corynebacterium</italic>.</p></sec><sec id="Sec5"><title>Bacteriophages</title><p id="Par14">Delving deeper into the bacteria of the microbiome brings us to bacteriophages. Bacteriophages, or viruses that infect bacteria, can be found throughout the biosphere, are essential members of the human microbiome, and may play an important regulatory role in human skin health and disease [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. Little is known about bacteriophage interaction with skin microbiota. Bacteriophages are obligatory intracellular parasites; thereby, their distribution depends on their host organisms [<xref ref-type="bibr" rid="CR50">50</xref>]. There are over 6000 well-known bacteriophages [<xref ref-type="bibr" rid="CR53">53</xref>], and these bacteriophages are estimated to be&#x000a0;at least tenfold more common than bacteria [<xref ref-type="bibr" rid="CR14">14</xref>]. There is wide diversity in the structure of these phages (e.g., tailed, polyhedral, pleomorphic, filamentous), and they are usually classified based on their genetic content [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par15">Four distinct life cycle phases have been described: lytic (virulent phages), lysogenic, pseudo-lysogenic (temperate phages), and chronic infection [<xref ref-type="bibr" rid="CR53">53</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The first step in every phage cycle is the binding of the phage to bacterial surface receptors, after which the phage injects its genetic material (DNA or RNA) into the cells [<xref ref-type="bibr" rid="CR54">54</xref>]. Phages undergoing the lytic phase, also called virulent phages, are the most abundant type and the most widely used in bacteriophage therapy due to their natural ability to kill bacteria directly through cell lysis.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>The cell cycle of bacteriophages</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Life cycle</th><th align="left">Description</th></tr></thead><tbody><tr><td align="left">Lytic (or virulent) phages</td><td align="left">Bacteriophage genes are extensively replicated, transcribed, and expressed in the cytoplasm of infected bacteria. These genes encode for the synthesis of certain phage proteins, such as lysins, holins, and murin. The proteins assemble into phage progeny, which are released from the cell and cause rapid cell lysis</td></tr><tr><td align="left">Lysogenic (temperate or dormant) phages</td><td align="left">Phage genes are integrated into host chromosomes or exist as extrachromosomal plasmids and undergo replication with the cell&#x02019;s normal replication cycle until the phage re-enters the lytic phase. No phage progeny are produced. These phages are capable of transduction, or the ability to transfer bacterial DNA into the host genome. Transduction can confer pathogenicity or antibiotic resistance to the bacteria and leads to a genetically altered daughter cell</td></tr><tr><td align="left">Pseudo-lysogenic phages</td><td align="left">These phages remain dormant in the bacterial cell (typically due to the nutritional deficiencies of the cell) without integration into the cell&#x02019;s genome and without causing cell lysis until more favorable environmental conditions allow the phages to enter either a lytic or lysogenic cycle</td></tr><tr><td align="left">Chronic infection</td><td align="left">Slow and chronic release of phage progeny from the cell without causing cell death</td></tr></tbody></table><table-wrap-foot><p>Data on bacteriophage cell cycle are noted in detail in references [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]</p></table-wrap-foot></table-wrap></p><p id="Par16">Phages (temperate or dormant phages) that enter the lysogenic phase have the ability to induce transduction [<xref ref-type="bibr" rid="CR53">53</xref>], a vital process in bacterial pathogenesis and adaptation [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Transduction can confer advantages to bacteria by transferring pathogenicity or antibiotic resistance genes [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Due to this risk, only those bacteriophages with lytic activity should be considered in phage therapy [<xref ref-type="bibr" rid="CR53">53</xref>]. However, transduction can be used to our benefit by genetically engineering phages to transfer genes to reverse antibiotic resistance or to increase bacterial susceptibility to antibiotics [<xref ref-type="bibr" rid="CR29">29</xref>]. Edgar et al. restored antibiotic sensitivity to streptomycin and nalidixic acid in resistant <italic>Escherichia coli</italic> in an in vitro study using genetically engineered bacteriophages [<xref ref-type="bibr" rid="CR58">58</xref>]. In another study, Lue and Collins used genetically engineered phages to transfer genes that target DNA repair mechanisms, resulting in an increase in <italic>E. coli</italic> susceptibility to quinolones in vitro and in vivo [<xref ref-type="bibr" rid="CR59">59</xref>]. These studies show that engineered bacteriophages can enhance the killing of antibiotic-resistant bacteria and biofilm and reduce the emergence of antibiotic resistance in bacteria.</p><sec id="Sec6"><title><italic>Propionibacterium acnes</italic> Bacteriophages</title><p id="Par17"><italic>Propionibacterium acnes</italic> bacteriophages were first identified by Brzin in 1964 [<xref ref-type="bibr" rid="CR60">60</xref>]. In 1968, Zierdtc et al. isolated phage 174 from <italic>Corynebacterium acnes</italic> strains and used it to classify the <italic>Corynebacterium</italic> family, ultimately finding that 88% of all <italic>C. acnes</italic> strains were sensitive to this bacteriophage [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. A later study reported that 18% of <italic>P. acnes</italic> phages carried bacteriophages [<xref ref-type="bibr" rid="CR62">62</xref>], and <italic>P. acnes</italic> bacteriophages were subsequently used to classify <italic>Corynebacterium</italic> and <italic>Propionibacterium</italic> [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par18"><italic>P. acnes</italic> bacteriophages are relatively more abundant in lipid-rich areas of the skin, correlating with the distribution of <italic>P. acnes</italic> in the skin [<xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR67">67</xref>]. These bacteriophages are the dominant phages in the pilosebaceous unit. Fitz-Gibbon et al. reported a 1:120 bacteriophages:<italic>P. acnes</italic> ratio in pilosebaceous units in healthy skin samples [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Most <italic>P. acnes</italic> bacteriophages possess a siphoviral morphology (i.e., isometric head and long flexible tail) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>] and have a pseudolysogenic life cycle (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. <italic>P. bacteriophages</italic> displaying a lytic life cycle have also been characterized [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par19">Interestingly, despite the isolation of <italic>P. acnes</italic> bacteriophages over a varied temporal and geographical range, their genome is preserved with very limited genetic diversity [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Marinelli et al. investigated the diversity of bacteriophages that infect <italic>P. acnes</italic> and isolated 11 <italic>P. acnes</italic> bacteriophages which lacked the genetic diversity seen in other phage populations [<xref ref-type="bibr" rid="CR15">15</xref>]. A recent study by Liu et al. sequenced 48 <italic>P. acnes</italic> bacteriophages from human skin follicles and found a sequence identity of between 85 and 100% between strains, suggesting that the <italic>P. acnes</italic> bacteriophage population in the skin microbiota is dominated by one strain [<xref ref-type="bibr" rid="CR8">8</xref>]. The authors tested the <italic>P. acnes</italic>&#x02013;bacteriophage interaction and found that the 74 <italic>P. acnes</italic> strains were susceptible to the 15 tested <italic>P. acnes</italic> bacteriophages. They suggested multiple reasons for the lack of phage diversity, including a bottle-neck hypothesis leaving one dominant genotype, or the evolutionary constrains imposed on phages and bacteria to maintain a single phage, thus limiting the spreading of phage resistance [<xref ref-type="bibr" rid="CR8">8</xref>]. Another possible explanation for the limited diversity of <italic>P. acnes</italic> bacteriophages could be due to the niche in which they live, as <italic>P. acnes</italic> makes up 90% of the microbiota of the pilosebaceous unit, thereby limiting horizontal gene transfer and increased diversity between phages in the pilosebaceous unit [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par20">Liu et al. also found that some individuals shared the same bacteriophage strains in the skin microbiota, suggesting the existence of a pool of common bacteriophages among human populations [<xref ref-type="bibr" rid="CR8">8</xref>]. They further discovered identical bacteriophages strains between closely related individuals (siblings), which makes human to human virus transmission a possibility. As seen in other studies [<xref ref-type="bibr" rid="CR15">15</xref>], the resistance of certain<italic> P. acnes</italic> strains to bacteriophages was an issue [<xref ref-type="bibr" rid="CR8">8</xref>]. Two possible resistance mechanisms are described by these authors, namely, restriction modification and clustered regularly interspaced short palindromic repeat (CRISPR), both of which target viral DNA integration into the host genome [<xref ref-type="bibr" rid="CR8">8</xref>]. The findings of this study led the authors to conclude that the ability of <italic>P. acnes</italic> bacteriophages to lyse only susceptible strains may alter the bacteria population, as different strains will grow at different rates, thereby modulating the composition and dynamics of the skin microbiota.</p><p id="Par21">The apparent lack of genetic diversity of <italic>P. acnes</italic> bacteriophages and their broad host range make them ideal candidates for phage therapy in acne [<xref ref-type="bibr" rid="CR14">14</xref>]. Moreover, lytic bacteriophages engineered to target <italic>P. acnes</italic> strains in the specific microbiome of individuals will increase the success rate of acne treatments.</p></sec><sec id="Sec7"><title><italic>Propionibacterium acnes</italic> Bacteriophage Therapy</title><p id="Par22">The potential role of bacteriophage therapy in acne vulgaris has recently attracted the interest of researchers and clinicians. Phages active against <italic>P. acnes</italic> have been isolated from the skin, oral cavity, and gastrointestinal tract [<xref ref-type="bibr" rid="CR14">14</xref>]. It is important to note that only phages with proven lytic activity should be used in phage therapy because lysogenic or temperate phages carry the risk for transduction of antibiotic resistance or pathogenicity genes and may lead to delayed cell lysis [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par23">Bacteriophage therapy has been used in humans for several types of infections with good results [<xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR78">78</xref>]. However, no trials on <italic>P. acnes</italic> bacteriophage therapy have been conducted in humans. Brown et al. isolated ten bacteriophages capable of lysing <italic>P. acnes</italic> from human skin microbiota and tested their therapeutic potential [<xref ref-type="bibr" rid="CR72">72</xref>]. These authors created a suspension for each bacteriophage at a final concentration of 2.5&#x02009;&#x000d7;&#x02009;10<sup>8</sup>&#x000a0;PFU/g using an aqueous cetomacrogol cream that&#x000a0;showed that these bacteriophage formulations effectively lysed <italic>P. acnes</italic> cells in agar lawn culture plates and remained active in the cream for up to 90&#x000a0;days when stored at 4 &#x000b0;C in light-protected bottles. The bacteriophage was specific to <italic>P. acnes</italic> strains and did not lyse other bacteria of the <italic>Propionibacterium</italic> family. Cells that regrew from the areas within the <italic>P. acnes</italic> plaques showed phage resistance [<xref ref-type="bibr" rid="CR72">72</xref>]. Although some authors have suggested that a cocktail of phages could be used to decrease the risk of phage resistance [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], <italic>P. acnes</italic> bacteriophage variability is relatively low, which may limit this approach. This important limitation needs to be explored in further studies. However, the results using the cream formulation of Brown et al. [<xref ref-type="bibr" rid="CR72">72</xref>] suggest that <italic>P. acnes</italic> bacteriophage therapy is a simple and realistic therapeutic option for the treatment of acne. Another in vitro study showed effective eradication of <italic>P. acnes</italic> strains when <italic>P. acnes</italic> bacteriophages were isolated from human skin microbiota and applied in drops onto agar plates [<xref ref-type="bibr" rid="CR79">79</xref>]. In this study, <italic>P. acnes</italic> bacteriophages were unable to kill other bacteria, such as <italic>Staphylococcus aureus</italic>, <italic>S. epidermidis</italic>, and <italic>Corynebacterium xerosis</italic>, confirming the specificity of these bacteriophages [<xref ref-type="bibr" rid="CR79">79</xref>]. Formulations such as oil&#x02013;base cream, water&#x02013;oil nanoemulsion, biodegradable polyester matrix, antiseptic gel, and paraffin-oil-based lotion, have proven to be effective strategies to deliver bacteriophages [<xref ref-type="bibr" rid="CR80">80</xref>].</p><p id="Par24"><italic>P. acnes</italic> bacteriophage genomes encode endolysins involved in bacteria cell-wall degradation (muramidases, amidases, endopeptidases, glucosaminidases, and transglycosylases) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. These endolysins are implicated in the release of progeny following phage assembly by targeting peptidoglycan in the bacterial wall [<xref ref-type="bibr" rid="CR70">70</xref>]. Marinelli et al. suggested that endolysins are a potential therapeutic option in acne therapy [<xref ref-type="bibr" rid="CR15">15</xref>]. Phage endolysins are highly conserved in different <italic>P. acnes</italic> bacteriophage strains (95% at the amino acid level) [<xref ref-type="bibr" rid="CR15">15</xref>], which implies that endolysins from any <italic>P. acnes</italic> bacteriophage could be active against most <italic>P. acnes</italic> strains. Phage endolysins have been used as antimicrobials both in vitro and in vivo with promising results [<xref ref-type="bibr" rid="CR82">82</xref>]. Furthermore, no resistance to phage endolysins has been reported [<xref ref-type="bibr" rid="CR82">82</xref>]. It has been shown that even bacteria that become phage resistant may remain endolysin sensitive [<xref ref-type="bibr" rid="CR14">14</xref>]. This introduces yet another way to treat acne through the genetic engineering of enzymes to target bacteria cell walls.</p><p id="Par25">These possibilities carry important therapeutic implications in the management of acne. Antibiotics, in combination with bacteriophage cocktails, could be used to decrease antibiotic resistance and to treat antibiotic-resistant <italic>P. acnes</italic>. However, further research is needed to evaluate <italic>P. acnes</italic> bacteriophage therapy in human subjects, both as monotherapy and in combination with conventional therapies.</p></sec><sec id="Sec8"><title>Advantages of Phage Therapy</title><p id="Par26">Bacteriophages have a low environmental impact compared to chemical antibiotics due to their natural origin [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. They target both Gram-positive and Gram-negative bacteria [<xref ref-type="bibr" rid="CR84">84</xref>&#x02013;<xref ref-type="bibr" rid="CR92">92</xref>], and many in vitro and in vivo models have shown that bacteriophages are effective against multidrug-resistant bacteria [<xref ref-type="bibr" rid="CR85">85</xref>&#x02013;<xref ref-type="bibr" rid="CR88">88</xref>]. As antibiotic resistance grows, phages retain the ability to kill antibiotic-resistant bacteria due to their differing mechanisms of action [<xref ref-type="bibr" rid="CR53">53</xref>]. Bacteriophages are specific to their bacterial hosts (species), and only replicate locally, limiting the pressure on normal non-targeted flora of the skin and other organs [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. Bacteriophages have also been shown to distribute in good concentrations all over the body, including the central nervous system [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR95">95</xref>] (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Advantages and disadvantages of phage therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Advantages</th><th align="left">Limitations</th></tr></thead><tbody><tr><td align="left">Low environmental impact</td><td align="left">Poor understanding of phage life cycle</td></tr><tr><td align="left">Cover Gram-positive and Gram-negative bacteria</td><td align="left">Transduction of phage genome into human host</td></tr><tr><td align="left">No cross-resistance with antibiotics</td><td align="left">Transduction of pathogenicity genes</td></tr><tr><td align="left">Host specificity</td><td align="left">Low variability of <italic>P. acnes</italic> bacteriophage</td></tr><tr><td align="left">Low risk of phage resistance</td><td align="left">Phage resistance</td></tr><tr><td align="left">Can clear biofilm</td><td align="left">Large release of bacterial endotoxin (lipopolysaccharides)</td></tr><tr><td align="left">Transduction of susceptibility genes</td><td align="left"/></tr><tr><td align="left">Rapid isolation of phage</td><td align="left">Optimal dose, route of administration, frequency, and duration of treatment are not known</td></tr><tr><td align="left">Low cost of phage therapy</td><td align="left">Lack of standardized guidelines to generate phage cocktails</td></tr><tr><td align="left">Good safety profile</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Data on the advantages and disadvantages of phage therapy are noted in detail in references [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]</p></table-wrap-foot></table-wrap></p><p id="Par27">Another potential benefit of bacteriophage therapy is the ability to decrease biofilm formation [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR96">96</xref>&#x02013;<xref ref-type="bibr" rid="CR101">101</xref>]. Many in vitro and in vivo studies have proven that the combination therapy of antibiotics and lytic bacteriophages displays synergism by improving the efficacy of bacteria and biofilm eradication and preventing the emergence of resistant bacteria [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR102">102</xref>&#x02013;<xref ref-type="bibr" rid="CR111">111</xref>]. Antibiotics could be conjugated with bacteriophages to deliver antibiotics to specific bacteria and at higher concentrations [<xref ref-type="bibr" rid="CR14">14</xref>]. Furthermore, engineered bacteriophages could be used to improve efficacy through the transfer of susceptibility or sensitizing genes by means of genetic engineering.</p><p id="Par28">The identification of bacteria and bacteriophage isolation for therapeutic purposes is a rapid and affordable process compared to the development of new antibiotics [<xref ref-type="bibr" rid="CR93">93</xref>]. Moreover, the cost of bacteriophage therapy seems to be lower than that of traditional antibiotic therapy [<xref ref-type="bibr" rid="CR112">112</xref>]; however, more studies are needed to establish the real short- or long-term costs of bacteriophage therapy.</p><p id="Par29">Finally, bacteriophages are safe and well-tolerated, and no significant adverse events have been reported [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>].</p></sec><sec id="Sec9"><title>Limitations of Bacteriophage Therapy</title><p id="Par30">Although the prospect of using bacteriophage therapy to treat acne in a world with increasing antibiotic resistance is promising, this novel therapeutic endeavor comes with limitations. The first of these is our evolving understanding of phages and their life cycles. The newest data suggests that phages exist on a continuum between lytic and lysogenic life cycles [<xref ref-type="bibr" rid="CR115">115</xref>]. This creates challenges when using phages as therapeutic vehicles since conventional phage therapy requires phages to undergo lytic cycles and rapidly kill their hosts. Most <italic>P. acnes</italic> phages characterized thus far, however, display pseudolysogeny (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par31">In addition, CRISPR protects bacteria from viral DNA integration, and <italic>P. acnes</italic> may become resistant to phage therapy through this mechanism [<xref ref-type="bibr" rid="CR54">54</xref>]. This issue of resistance becomes even more likely with the knowledge that bacteriophages targeting <italic>P. acnes</italic> are highly homogeneous [<xref ref-type="bibr" rid="CR26">26</xref>]. Therefore, the acquisition of resistance to one phage may confer <italic>P. acnes</italic> with resistance to many of its bacteriophages [<xref ref-type="bibr" rid="CR14">14</xref>]. However, the risk is low compared to antibiotics, partially because bacteriophages can mutate and bypass bacteriophage resistance mechanisms [<xref ref-type="bibr" rid="CR93">93</xref>]. Resistance can also be prevented by using multiple bacteriophages (cocktails) or synergistic combinations of bacteriophages + antibiotics [<xref ref-type="bibr" rid="CR93">93</xref>].</p><p id="Par32">In addition to these limitations, the more practical aspects of establishing optimal therapeutic doses, treatment frequency, and duration have not been established [<xref ref-type="bibr" rid="CR54">54</xref>]. A more long-term risk with this therapy includes the unknown consequences to the cutaneous microbiome if <italic>P. acnes</italic>, a vital member to this community, is temporarily eradicated through acne treatment. We do not fully understand the repercussions of altering the natural micro-ecosystem of the skin.</p></sec><sec id="Sec10"><title>Future therapeutic option</title><p id="Par33">As the antibiotic resistance era approaches, research on new alternative antimicrobial agents is becoming critical. Bacteriophages, ubiquitous microorganisms of the human skin microbiome, contain distinct advantages that mark them as promising alternatives to conventional antimicrobial therapy. Among these advantages are host specificity, limited cross resistance, ease of isolation, low cost, and a favorable safety profile compared to antibiotics.</p><p id="Par34">The potential clinical application of bacteriophage therapy for acne vulgaris is promising. Limitations to phage therapy, such as the risk of transduction of pathogenicity genes and the low <italic>P. acnes</italic> bacteriophage variability, can be overcome by a more thorough understanding of the bacteria&#x02013;bacteriophage interaction in the human skin microbiome. Phage resistance is another limitation that must be considered and warrants further study.</p><p id="Par35">As the field develops, more data is needed before phage therapy in human subjects is introduced. Developing targeted phage therapy, engineered bacteriophages, and enzyme-based therapies, either alone or as an adjuvant to antibiotics, may lead to decreasing rates of<italic> P. acnes</italic> resistance to antibiotics and the restoration of antibiotic susceptibility to<italic> P. acnes</italic>.</p></sec></sec></body><back><fn-group><fn><p><bold>Enhanced Digital Features</bold></p><p>To view enhanced digital features for this article go to 10.6084/m9.figshare.7376021.</p></fn></fn-group><ack><title>Acknowledgements</title><sec id="FPar1"><title>Funding</title><p id="Par36">No funding sources were used for the development of this review.</p></sec><sec id="FPar2"><title>Authorship</title><p id="Par37">All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.</p></sec><sec id="FPar3"><title>Disclosures</title><p id="Par38">David E. Castillo, Sonali Nanda, and Jonette E. Keri declare have nothing to disclose.</p></sec><sec id="FPar4"><title>Compliance with Ethics Guidelines</title><p id="Par39">This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.</p></sec><sec id="d29e1418"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zaenglein</surname><given-names>A</given-names></name><name><surname>Thiboutot</surname><given-names>D</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Bolognia</surname><given-names>J</given-names></name><name><surname>Schaffer</surname><given-names>J</given-names></name><name><surname>Cerroni</surname><given-names>L</given-names></name></person-group><article-title>Acne vulgaris</article-title><source>Dermatology</source><year>2012</year><edition>4</edition><publisher-loc>Amsterdam</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>588</fpage><lpage>603</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>R</given-names></name><name><surname>Johns</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>H</given-names></name><etal/></person-group><article-title>The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions</article-title><source>J Investig Dermatol</source><year>2013</year><volume>134</volume><fpage>1527</fpage><lpage>1534</lpage><?supplied-pmid 24166134?><pub-id pub-id-type="pmid">24166134</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimkhani</surname><given-names>C</given-names></name><name><surname>Dellavalle</surname><given-names>RP</given-names></name><name><surname>Coffeng</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Global skin disease morbidity and mortality: an update from the global burden of disease study 2013</article-title><source>JAMA Dermatol</source><year>2017</year><volume>153</volume><issue>5</issue><fpage>406</fpage><lpage>412</lpage><?supplied-pmid 28249066?><pub-id pub-id-type="pmid">28249066</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynn</surname><given-names>DD</given-names></name><name><surname>Umari</surname><given-names>T</given-names></name><name><surname>Dunnick</surname><given-names>CA</given-names></name><name><surname>Dellavalle</surname><given-names>RP</given-names></name></person-group><article-title>The epidemiology of acne vulgaris in late adolescence</article-title><source>Adolesc Health Med Ther</source><year>2016</year><volume>7</volume><fpage>13</fpage><lpage>25</lpage><?supplied-pmid 26955297?><pub-id pub-id-type="pmid">26955297</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidbury</surname><given-names>R</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name></person-group><article-title>The diagnosis and management of acne</article-title><source>Pediatr Ann</source><year>2000</year><volume>29</volume><issue>1</issue><fpage>17</fpage><lpage>24</lpage><?supplied-pmid 10941764?><pub-id pub-id-type="pmid">10941764</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>GM</given-names></name></person-group><article-title>Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris</article-title><source>J Am Acad Dermatol</source><year>1998</year><volume>39</volume><fpage>S34</fpage><lpage>S37</lpage><?supplied-pmid 9703121?><pub-id pub-id-type="pmid">9703121</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halvorsen</surname><given-names>JA</given-names></name><name><surname>Stern</surname><given-names>RS</given-names></name><name><surname>Dalgard</surname><given-names>F</given-names></name><name><surname>Thoresen</surname><given-names>M</given-names></name><name><surname>Bjertness</surname><given-names>E</given-names></name><name><surname>Lien</surname><given-names>L</given-names></name></person-group><article-title>Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study</article-title><source>J Investig Dermatol</source><year>2011</year><volume>131</volume><issue>2</issue><fpage>363</fpage><lpage>370</lpage><?supplied-pmid 20844551?><pub-id pub-id-type="pmid">20844551</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The diversity and host interactions of <italic>Propionibacterium acnes</italic> bacteriophages on human skin</article-title><source>ISME J</source><year>2015</year><volume>9</volume><issue>9</issue><fpage>2078</fpage><lpage>2093</lpage><?supplied-pmid 25848871?><pub-id pub-id-type="pmid">25848871</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">World Health Organization (WHO). Antimicrobial resistance: global report on surveillance. 2014. Available online at: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf">http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf</ext-link>. Accessed 30 June 2018.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname><given-names>P</given-names></name><name><surname>Vyakrnam</surname><given-names>S</given-names></name><name><surname>Eady</surname><given-names>EA</given-names></name><name><surname>Jones</surname><given-names>CE</given-names></name><name><surname>Cove</surname><given-names>JH</given-names></name><name><surname>Cunliffe</surname><given-names>WJ</given-names></name></person-group><article-title>Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study</article-title><source>Br J Dermatol</source><year>2002</year><volume>146</volume><issue>5</issue><fpage>840</fpage><lpage>848</lpage><?supplied-pmid 12000382?><pub-id pub-id-type="pmid">12000382</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholz</surname><given-names>CF</given-names></name><name><surname>Kilian</surname><given-names>M</given-names></name></person-group><article-title>The natural history of cutaneous propionibacteria, and reclassification of selected species within the genus Propionibacterium to the proposed novel genera <italic>Acidipropionibacterium</italic> gen. nov., <italic>Cutibacterium</italic> gen. nov. and <italic>Pseudopropionibacterium</italic> gen. nov.</article-title><source>Int J Syst Evol Microbiol</source><year>2016</year><volume>66</volume><issue>11</issue><fpage>4422</fpage><lpage>4432</lpage><?supplied-pmid 27488827?><pub-id pub-id-type="pmid">27488827</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dessinioti</surname><given-names>C</given-names></name><name><surname>Katsambas</surname><given-names>A</given-names></name></person-group><article-title><italic>Propionibacterium acnes</italic> and antimicrobial resistance in acne</article-title><source>Clin Dermatol</source><year>2017</year><volume>35</volume><issue>2</issue><fpage>163</fpage><lpage>167</lpage><?supplied-pmid 28274353?><pub-id pub-id-type="pmid">28274353</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PF</given-names></name><name><surname>Hsieh</surname><given-names>YD</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Two</surname><given-names>A</given-names></name><name><surname>Shu</surname><given-names>CW</given-names></name><name><surname>Huang</surname><given-names>CM</given-names></name></person-group><article-title><italic>Propionibacterium acnes</italic> in the pathogenesis and immunotherapy of acne vulgaris</article-title><source>Curr Drug Metab</source><year>2015</year><volume>16</volume><issue>4</issue><fpage>245</fpage><lpage>254</lpage><?supplied-pmid 26264195?><pub-id pub-id-type="pmid">26264195</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonczyk-Matysiak</surname><given-names>E</given-names></name><name><surname>Weber-Dabrowska</surname><given-names>B</given-names></name><name><surname>Zaczek</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prospects of phage application in the treatment of acne caused by <italic>Propionibacterium acnes</italic></article-title><source>Front Microbiol</source><year>2017</year><volume>8</volume><fpage>164</fpage><?supplied-pmid 28228751?><pub-id pub-id-type="pmid">28228751</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marinelli</surname><given-names>LJ</given-names></name><name><surname>Fitz-Gibbon</surname><given-names>S</given-names></name><name><surname>Hayes</surname><given-names>C</given-names></name><etal/></person-group><article-title><italic>Propionibacterium acnes</italic> bacteriophages display limited genetic diversity and broad killing activity against bacterial skin isolates</article-title><source>MBio</source><year>2012</year><volume>3</volume><issue>5</issue><fpage>e00279</fpage><pub-id pub-id-type="doi">10.1128/mBio.00279-12</pub-id><?supplied-pmid 23015740?><pub-id pub-id-type="pmid">23015740</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGinley</surname><given-names>KJ</given-names></name><name><surname>Webster</surname><given-names>GF</given-names></name><name><surname>Ruggieri</surname><given-names>MR</given-names></name><name><surname>Leyden</surname><given-names>JJ</given-names></name></person-group><article-title>Regional variations in density of cutaneous propionibacteria: correlation of <italic>Propionibacterium acnes</italic> populations with sebaceous secretion</article-title><source>J Clin Microbiol</source><year>1980</year><volume>12</volume><issue>5</issue><fpage>672</fpage><lpage>675</lpage><?supplied-pmid 7276142?><pub-id pub-id-type="pmid">7276142</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brzuszkiewicz</surname><given-names>E</given-names></name><name><surname>Weiner</surname><given-names>J</given-names></name><name><surname>Wollherr</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparative genomics and transcriptomics of <italic>Propionibacterium acnes</italic></article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>6</issue><fpage>e21581</fpage><?supplied-pmid 21738717?><pub-id pub-id-type="pmid">21738717</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>HH</given-names></name><name><surname>Segre</surname><given-names>JA</given-names></name></person-group><article-title>Skin microbiome: looking back to move forward</article-title><source>J Investig Dermatol</source><year>2012</year><volume>132</volume><issue>3 Pt 2</issue><fpage>933</fpage><lpage>939</lpage><?supplied-pmid 22189793?><pub-id pub-id-type="pmid">22189793</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyner</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name></person-group><article-title><italic>Propionibacterium acnes</italic> biofilm&#x02014;a sanctuary for <italic>Staphylococcus aureus</italic>?</article-title><source>Anaerobe</source><year>2016</year><volume>40</volume><fpage>63</fpage><lpage>67</lpage><?supplied-pmid 27241780?><pub-id pub-id-type="pmid">27241780</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ochoa</surname><given-names>MT</given-names></name><name><surname>Krutzik</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><issue>3</issue><fpage>1535</fpage><lpage>1541</lpage><?supplied-pmid 12133981?><pub-id pub-id-type="pmid">12133981</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeremy</surname><given-names>AH</given-names></name><name><surname>Holland</surname><given-names>DB</given-names></name><name><surname>Roberts</surname><given-names>SG</given-names></name><name><surname>Thomson</surname><given-names>KF</given-names></name><name><surname>Cunliffe</surname><given-names>WJ</given-names></name></person-group><article-title>Inflammatory events are involved in acne lesion initiation</article-title><source>J Investig Dermatol</source><year>2003</year><volume>121</volume><issue>1</issue><fpage>20</fpage><lpage>27</lpage><?supplied-pmid 12839559?><pub-id pub-id-type="pmid">12839559</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vowels</surname><given-names>BR</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Leyden</surname><given-names>JJ</given-names></name></person-group><article-title>Induction of proinflammatory cytokines by a soluble factor of <italic>Propionibacterium acnes</italic>: implications for chronic inflammatory acne</article-title><source>Infect Immun</source><year>1995</year><volume>63</volume><issue>8</issue><fpage>3158</fpage><lpage>3165</lpage><?supplied-pmid 7542639?><pub-id pub-id-type="pmid">7542639</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>I</given-names></name><name><surname>Pivarcsi</surname><given-names>A</given-names></name><name><surname>Kis</surname><given-names>K</given-names></name><etal/></person-group><article-title><italic>Propionibacterium acnes</italic> and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes</article-title><source>Microbes Infect</source><year>2006</year><volume>8</volume><issue>8</issue><fpage>2195</fpage><lpage>2205</lpage><?supplied-pmid 16797202?><pub-id pub-id-type="pmid">16797202</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>H</given-names></name><name><surname>Suh</surname><given-names>D</given-names></name></person-group><article-title>Recent progress in the research about <italic>Propionibacterium acnes</italic> strain diversity and acne: pathogen or bystander?</article-title><source>Int J Dermatol</source><year>2016</year><volume>55</volume><issue>11</issue><fpage>1196</fpage><lpage>1204</lpage><?supplied-pmid 27421121?><pub-id pub-id-type="pmid">27421121</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahns</surname><given-names>A</given-names></name><name><surname>Lundskog</surname><given-names>B</given-names></name><name><surname>Dahlberg</surname><given-names>I</given-names></name><name><surname>Tamayo</surname><given-names>N</given-names></name><name><surname>McDowell</surname><given-names>A</given-names></name><name><surname>Patrick</surname><given-names>S</given-names></name><etal/></person-group><article-title>No link between rosacea and <italic>Propionibacterium acnes</italic></article-title><source>APMIS</source><year>2012</year><volume>120</volume><issue>11</issue><fpage>922</fpage><lpage>925</lpage><?supplied-pmid 23009116?><pub-id pub-id-type="pmid">23009116</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitz-Gibbon</surname><given-names>S</given-names></name><name><surname>Tomida</surname><given-names>S</given-names></name><name><surname>Chiu</surname><given-names>BH</given-names></name><etal/></person-group><article-title><italic>Propionibacterium acnes</italic> strain populations in the human skin microbiome associated with acne</article-title><source>J Investig Dermatol</source><year>2013</year><volume>133</volume><issue>9</issue><fpage>2152</fpage><lpage>2160</lpage><?supplied-pmid 23337890?><pub-id pub-id-type="pmid">23337890</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomholt</surname><given-names>HB</given-names></name><name><surname>Kilian</surname><given-names>M</given-names></name></person-group><article-title>Population genetic analysis of <italic>Propionibacterium acnes</italic> identifies a subpopulation and epidemic clones associated with acne</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><issue>8</issue><fpage>e12277</fpage><?supplied-pmid 20808860?><pub-id pub-id-type="pmid">20808860</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodes</surname><given-names>MJ</given-names></name><name><surname>Secrist</surname><given-names>H</given-names></name><name><surname>Benson</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Variable expression of immunoreactive surface proteins of <italic>Propionibacterium acnes</italic></article-title><source>Microbiology</source><year>2006</year><volume>152</volume><issue>Pt 12</issue><fpage>3667</fpage><lpage>3681</lpage><?supplied-pmid 17159220?><pub-id pub-id-type="pmid">17159220</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jassim</surname><given-names>A</given-names></name><name><surname>Limoges</surname><given-names>R</given-names></name></person-group><article-title>Natural solution to antibiotic resistance: bacteriophages &#x0201c;The Living Drugs&#x0201d;</article-title><source>World J Microbiol Biotechnol</source><year>2014</year><volume>30</volume><fpage>2153</fpage><lpage>2170</lpage><?supplied-pmid 24781265?><pub-id pub-id-type="pmid">24781265</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention (CDC). Antibiotic use in the United States, 2017: progress and opportunities. Atlanta: US Department of Health and Human Services; 2017.</mixed-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zucca</surname><given-names>M</given-names></name><name><surname>Savoia</surname><given-names>D</given-names></name></person-group><article-title>The post-antibiotic era: promising developments in the therapy of infectious diseases</article-title><source>Int J Biomed Sci</source><year>2010</year><volume>6</volume><issue>2</issue><fpage>77</fpage><lpage>86</lpage><?supplied-pmid 23675180?><pub-id pub-id-type="pmid">23675180</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>T</given-names></name></person-group><article-title>Drug companies snub antibiotics as pipeline threatens to run dry</article-title><source>Nature</source><year>2003</year><volume>425</volume><fpage>225</fpage><?supplied-pmid 13679874?><pub-id pub-id-type="pmid">13679874</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadhasivam</surname><given-names>S</given-names></name><name><surname>Sinha</surname><given-names>M</given-names></name><name><surname>Saini</surname><given-names>S</given-names></name><etal/></person-group><article-title>Heterogeneity and antibiotic resistance in <italic>Propionibacterium acnes</italic> isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes</article-title><source>Dermatol Ther</source><year>2016</year><volume>29</volume><issue>6</issue><fpage>451</fpage><lpage>454</lpage><?supplied-pmid 27424878?><pub-id pub-id-type="pmid">27424878</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2). 10.1128/microbiolspec.VMBF-0016-2015</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>N</given-names></name><name><surname>Hernandez</surname><given-names>PO</given-names></name><name><surname>Tyring</surname><given-names>SK</given-names></name><name><surname>Haitz</surname><given-names>KA</given-names></name><name><surname>Motta</surname><given-names>A</given-names></name></person-group><article-title>Antimicrobial susceptibility of <italic>Propionibacterium acnes</italic> isolates from acne patients in Colombia</article-title><source>Int J Dermatol</source><year>2013</year><volume>52</volume><issue>6</issue><fpage>688</fpage><lpage>692</lpage><?supplied-pmid 23451873?><pub-id pub-id-type="pmid">23451873</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>N</given-names></name><name><surname>Hui</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><etal/></person-group><article-title>Antibiotic-resistant <italic>Propionibacterium acnes</italic> among acne patients in a regional skin centre in Hong Kong</article-title><source>J Eur Acad Dermatol Venereol</source><year>2013</year><volume>27</volume><issue>1</issue><fpage>31</fpage><lpage>36</lpage><?supplied-pmid 22103749?><pub-id pub-id-type="pmid">22103749</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumont-Wallon</surname><given-names>G</given-names></name><name><surname>Moyse</surname><given-names>D</given-names></name><name><surname>Blouin</surname><given-names>E</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name></person-group><article-title>Bacterial resistance in French acne patients</article-title><source>Int J Dermatol</source><year>2010</year><volume>49</volume><issue>3</issue><fpage>283</fpage><lpage>288</lpage><?supplied-pmid 20465665?><pub-id pub-id-type="pmid">20465665</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eady</surname><given-names>EA</given-names></name><name><surname>Gloor</surname><given-names>M</given-names></name><name><surname>Leyden</surname><given-names>JJ</given-names></name></person-group><article-title><italic>Propionibacterium acnes</italic> resistance: a worldwide problem</article-title><source>Dermatology</source><year>2003</year><volume>206</volume><issue>1</issue><fpage>54</fpage><lpage>56</lpage><?supplied-pmid 12566805?><pub-id pub-id-type="pmid">12566805</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Reynaud</surname><given-names>A</given-names></name><name><surname>Moyse</surname><given-names>D</given-names></name><name><surname>Habert</surname><given-names>H</given-names></name><name><surname>Richet</surname><given-names>H</given-names></name></person-group><article-title>Erythromycin-resistance of cutaneous bacterial flora in acne</article-title><source>Eur J Dermatol</source><year>2001</year><volume>11</volume><issue>6</issue><fpage>549</fpage><lpage>553</lpage><?supplied-pmid 11701406?><pub-id pub-id-type="pmid">11701406</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>JI</given-names></name><name><surname>Snelling</surname><given-names>AM</given-names></name><name><surname>Carnegie</surname><given-names>E</given-names></name><etal/></person-group><article-title>Antibiotic-resistant acne: lessons from Europe</article-title><source>Br J Dermatol</source><year>2003</year><volume>148</volume><issue>3</issue><fpage>467</fpage><lpage>478</lpage><?supplied-pmid 12653738?><pub-id pub-id-type="pmid">12653738</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>HH</given-names></name><name><surname>Tan</surname><given-names>AW</given-names></name><name><surname>Barkham</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>XY</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name></person-group><article-title>Community-based study of acne vulgaris in adolescents in Singapore</article-title><source>Br J Dermatol</source><year>2007</year><volume>157</volume><issue>3</issue><fpage>547</fpage><lpage>551</lpage><?supplied-pmid 17655737?><pub-id pub-id-type="pmid">17655737</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurokawa</surname><given-names>I</given-names></name><name><surname>Nishijima</surname><given-names>S</given-names></name><name><surname>Kawabata</surname><given-names>S</given-names></name></person-group><article-title>Antimicrobial susceptibility of <italic>Propionibacterium acnes</italic> isolated from acne vulgaris</article-title><source>Eur J Dermatol</source><year>1999</year><volume>9</volume><issue>1</issue><fpage>25</fpage><lpage>28</lpage><?supplied-pmid 9920982?><pub-id pub-id-type="pmid">9920982</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishijima</surname><given-names>S</given-names></name><name><surname>Kurokawa</surname><given-names>I</given-names></name><name><surname>Katoh</surname><given-names>N</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name></person-group><article-title>The bacteriology of acne vulgaris and antimicrobial susceptibility of <italic>Propionibacterium acnes</italic> and <italic>Staphylococcus epidermidis</italic> isolated from acne lesions</article-title><source>J Dermatol</source><year>2000</year><volume>27</volume><issue>5</issue><fpage>318</fpage><lpage>323</lpage><?supplied-pmid 10875198?><pub-id pub-id-type="pmid">10875198</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkhart</surname><given-names>C</given-names></name><name><surname>Burkhart</surname><given-names>C</given-names></name></person-group><article-title>Microbiology&#x02019;s principle of biofilms as a major factor in the pathogenesis of acne vulgaris</article-title><source>Int J Dermatol</source><year>2003</year><volume>42</volume><fpage>925</fpage><lpage>927</lpage><?supplied-pmid 14636182?><pub-id pub-id-type="pmid">14636182</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Roling</surname><given-names>D</given-names></name><name><surname>Leyden</surname><given-names>J</given-names></name><name><surname>Margolis</surname><given-names>D</given-names></name></person-group><article-title>Effect of antibiotics on the oropharyngeal flora in patients with acne</article-title><source>Arch Dermatol</source><year>2003</year><volume>139</volume><fpage>467</fpage><lpage>471</lpage><?supplied-pmid 12707094?><pub-id pub-id-type="pmid">12707094</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>O</given-names><suffix>Jr</suffix></name><name><surname>Thornsberry</surname><given-names>C</given-names></name><name><surname>Cardin</surname><given-names>CW</given-names></name><name><surname>Smiles</surname><given-names>KA</given-names></name><name><surname>Leyden</surname><given-names>JJ</given-names></name></person-group><article-title>Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle</article-title><source>Acta Derm Venereol</source><year>2002</year><volume>82</volume><issue>4</issue><fpage>260</fpage><lpage>265</lpage><?supplied-pmid 12361129?><pub-id pub-id-type="pmid">12361129</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiboutot</surname><given-names>D</given-names></name><name><surname>Gollnick</surname><given-names>H</given-names></name><name><surname>Bettoli</surname><given-names>V</given-names></name><etal/></person-group><article-title>New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group</article-title><source>J Am Acad Dermatol</source><year>2009</year><volume>60</volume><fpage>1</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">19103358</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grice</surname><given-names>EA</given-names></name></person-group><article-title>The skin microbiome: potential for novel diagnostic and therapeutic approaches to cutaneous disease</article-title><source>Semin Cutan Med Surg</source><year>2014</year><volume>33</volume><issue>2</issue><fpage>98</fpage><lpage>103</lpage><?supplied-pmid 25085669?><pub-id pub-id-type="pmid">25085669</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Conlan</surname><given-names>S</given-names></name><name><surname>Polley</surname><given-names>EC</given-names></name><name><surname>Segre</surname><given-names>JA</given-names></name><name><surname>Kong</surname><given-names>HH</given-names></name></person-group><article-title>Shifts in human skin and nares microbiota of healthy children and adults</article-title><source>Genome Med</source><year>2012</year><volume>4</volume><issue>10</issue><fpage>77</fpage><?supplied-pmid 23050952?><pub-id pub-id-type="pmid">23050952</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clokie</surname><given-names>MR</given-names></name><name><surname>Millard</surname><given-names>AD</given-names></name><name><surname>Letarov</surname><given-names>AV</given-names></name><name><surname>Heaphy</surname><given-names>S</given-names></name></person-group><article-title>Phages in nature</article-title><source>Bacteriophage</source><year>2011</year><volume>1</volume><issue>1</issue><fpage>31</fpage><lpage>45</lpage><?supplied-pmid 21687533?><pub-id pub-id-type="pmid">21687533</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name></person-group><article-title>Isolation and characterization of an extremely long tail Thermus bacteriophage from Tengchong hot springs in China</article-title><source>J Basic Microbiol</source><year>2010</year><volume>50</volume><issue>5</issue><fpage>452</fpage><lpage>456</lpage><?supplied-pmid 20806260?><pub-id pub-id-type="pmid">20806260</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigent</surname><given-names>M</given-names></name><name><surname>Leroy</surname><given-names>M</given-names></name><name><surname>Confalonieri</surname><given-names>F</given-names></name><name><surname>Dutertre</surname><given-names>M</given-names></name><name><surname>DuBow</surname><given-names>M</given-names></name></person-group><article-title>A diversity of bacteriophage forms and genomes can be isolated from the surface sands of the Sahara Desert</article-title><source>Extremophiles</source><year>2005</year><volume>9</volume><issue>4</issue><fpage>289</fpage><lpage>296</lpage><?supplied-pmid 15947866?><pub-id pub-id-type="pmid">15947866</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittebole</surname><given-names>X</given-names></name><name><surname>De Roock</surname><given-names>S</given-names></name><name><surname>Opal</surname><given-names>S</given-names></name></person-group><article-title>A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens</article-title><source>Virulence</source><year>2014</year><volume>5</volume><issue>1</issue><fpage>226</fpage><lpage>235</lpage><?supplied-pmid 23973944?><pub-id pub-id-type="pmid">23973944</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruggemann</surname><given-names>H</given-names></name><name><surname>Lood</surname><given-names>R</given-names></name></person-group><article-title>Bacteriophages infecting <italic>Propionibacterium acnes</italic></article-title><source>Biomed Res Int</source><year>2013</year><volume>2013</volume><fpage>705741</fpage><?supplied-pmid 23691509?><pub-id pub-id-type="pmid">23691509</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Abedon S. Phages. In: Hyman P, Abedon S, eds. Bacteriophages in health and disease. AMCM 24 advances in molecular and cellular microbiology. Wallingford:CABI; 2012. Retrieved from <ext-link ext-link-type="uri" xlink:href="https://ebookcentral.proquest.com">https://ebookcentral.proquest.com</ext-link>. Accessed 7 July 2018.</mixed-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Shea</surname><given-names>YA</given-names></name><name><surname>Boyd</surname><given-names>EF</given-names></name></person-group><article-title>Mobilization of the Vibrio pathogenicity island between Vibrio cholerae isolates mediated by CP-T1 generalized transduction</article-title><source>FEMS Microbiol Lett</source><year>2002</year><volume>214</volume><issue>2</issue><fpage>153</fpage><lpage>157</lpage><?supplied-pmid 12351223?><pub-id pub-id-type="pmid">12351223</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiques</surname><given-names>E</given-names></name><name><surname>Ubeda</surname><given-names>C</given-names></name><name><surname>Tormo</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Role of staphylococcal phage and SaPI integrase in intra- and interspecies SaPI transfer</article-title><source>J Bacteriol</source><year>2007</year><volume>189</volume><issue>15</issue><fpage>5608</fpage><lpage>5616</lpage><?supplied-pmid 17545290?><pub-id pub-id-type="pmid">17545290</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgar</surname><given-names>R</given-names></name><name><surname>Friedman</surname><given-names>N</given-names></name><name><surname>Molshanski-Mor</surname><given-names>S</given-names></name><name><surname>Qimron</surname><given-names>U</given-names></name></person-group><article-title>Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes</article-title><source>Appl Environ Microbiol</source><year>2012</year><volume>78</volume><issue>3</issue><fpage>744</fpage><lpage>751</lpage><?supplied-pmid 22113912?><pub-id pub-id-type="pmid">22113912</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name></person-group><article-title>Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><issue>12</issue><fpage>4629</fpage><lpage>4634</lpage><?supplied-pmid 19255432?><pub-id pub-id-type="pmid">19255432</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brzin</surname><given-names>B</given-names></name></person-group><article-title>Studies on the <italic>Corynebacterium acnes</italic></article-title><source>Acta Pathol Microbiol Scand</source><year>1964</year><volume>60</volume><fpage>599</fpage><lpage>608</lpage><?supplied-pmid 14154722?><pub-id pub-id-type="pmid">14154722</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zierdt</surname><given-names>C</given-names></name><name><surname>Webster</surname><given-names>C</given-names></name><name><surname>Rude</surname><given-names>W</given-names></name></person-group><article-title>Study of the anaerobic corynebacteria</article-title><source>Int J Syst Evol Microbiol</source><year>1968</year><volume>18</volume><issue>1</issue><fpage>33</fpage><lpage>47</lpage></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>G</given-names></name><name><surname>Cummins</surname><given-names>C</given-names></name></person-group><article-title>Use of bacteriophage typing to distinguish <italic>Propionibacterium acne</italic> types I and II</article-title><source>J Clin Microbiol</source><year>1978</year><volume>7</volume><issue>1</issue><fpage>84</fpage><lpage>90</lpage><?supplied-pmid 624772?><pub-id pub-id-type="pmid">624772</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname><given-names>JG</given-names></name></person-group><article-title>Differentiation of two groups of <italic>Corynebacterium acnes</italic></article-title><source>J Bacteriol</source><year>1970</year><volume>101</volume><issue>2</issue><fpage>392</fpage><lpage>397</lpage><?supplied-pmid 4984071?><pub-id pub-id-type="pmid">4984071</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteside</surname><given-names>JA</given-names></name><name><surname>Voss</surname><given-names>JG</given-names></name></person-group><article-title>Incidence and lipolytic activity of <italic>Propionibacterium acnes</italic> (<italic>Corynebacterium acnes</italic> group I) and <italic>P. granulosum</italic> (<italic>C. acnes</italic> group II) in acne and in normal skin</article-title><source>J Investig Dermatol</source><year>1973</year><volume>60</volume><issue>2</issue><fpage>94</fpage><lpage>97</lpage><?supplied-pmid 4266325?><pub-id pub-id-type="pmid">4266325</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marples</surname><given-names>RR</given-names></name><name><surname>Leyden</surname><given-names>JJ</given-names></name><name><surname>Stewart</surname><given-names>RN</given-names></name><name><surname>Mills</surname><given-names>OH</given-names><suffix>Jr</suffix></name><name><surname>Kligman</surname><given-names>AM</given-names></name></person-group><article-title>The skin microflora in acne vulgaris</article-title><source>J Investig Dermatol</source><year>1974</year><volume>62</volume><issue>1</issue><fpage>37</fpage><lpage>41</lpage><?supplied-pmid 4271839?><pub-id pub-id-type="pmid">4271839</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marples</surname><given-names>RR</given-names></name><name><surname>McGinley</surname><given-names>KJ</given-names></name><name><surname>Mills</surname><given-names>OH</given-names></name></person-group><article-title>Microbiology of comedones in acne vulgaris</article-title><source>J Investig Dermatol</source><year>1973</year><volume>60</volume><issue>2</issue><fpage>80</fpage><lpage>83</lpage><?supplied-pmid 4266324?><pub-id pub-id-type="pmid">4266324</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puhvel</surname><given-names>SM</given-names></name><name><surname>Amirian</surname><given-names>DA</given-names></name></person-group><article-title>Bacterial flora of comedones</article-title><source>Br J Dermatol</source><year>1979</year><volume>101</volume><issue>5</issue><fpage>543</fpage><lpage>548</lpage><?supplied-pmid 160242?><pub-id pub-id-type="pmid">160242</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willner</surname><given-names>D</given-names></name><name><surname>Furlan</surname><given-names>M</given-names></name><name><surname>Schmieder</surname><given-names>R</given-names></name><etal/></person-group><article-title>Metagenomic detection of phage-encoded platelet-binding factors in the human oral cavity</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><issue>Suppl 1</issue><fpage>4547</fpage><lpage>4553</lpage><?supplied-pmid 20547834?><pub-id pub-id-type="pmid">20547834</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharon</surname><given-names>I</given-names></name><name><surname>Morowitz</surname><given-names>MJ</given-names></name><name><surname>Thomas</surname><given-names>BC</given-names></name><name><surname>Costello</surname><given-names>EK</given-names></name><name><surname>Relman</surname><given-names>DA</given-names></name><name><surname>Banfield</surname><given-names>JF</given-names></name></person-group><article-title>Time series community genomics analysis reveals rapid shifts in bacterial species, strains, and phage during infant gut colonization</article-title><source>Genome Res</source><year>2013</year><volume>23</volume><issue>1</issue><fpage>111</fpage><lpage>120</lpage><?supplied-pmid 3530670?><pub-id pub-id-type="pmid">22936250</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrar</surname><given-names>MD</given-names></name><name><surname>Howson</surname><given-names>KM</given-names></name><name><surname>Bojar</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Genome sequence and analysis of a <italic>Propionibacterium acnes</italic> bacteriophage</article-title><source>J Bacteriol</source><year>2007</year><volume>189</volume><issue>11</issue><fpage>4161</fpage><lpage>4167</lpage><?supplied-pmid 17400737?><pub-id pub-id-type="pmid">17400737</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lood</surname><given-names>R</given-names></name><name><surname>Collin</surname><given-names>M</given-names></name></person-group><article-title>Characterization and genome sequencing of two <italic>Propionibacterium acnes</italic> phages displaying pseudolysogeny</article-title><source>BMC Genom</source><year>2011</year><volume>12</volume><fpage>198</fpage></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>TL</given-names></name><name><surname>Petrovski</surname><given-names>S</given-names></name><name><surname>Dyson</surname><given-names>ZA</given-names></name><name><surname>Seviour</surname><given-names>R</given-names></name><name><surname>Tucci</surname><given-names>J</given-names></name></person-group><article-title>The formulation of bacteriophage in a semi solid preparation for control of <italic>Propionibacterium acnes</italic> growth</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>3</issue><fpage>e0151184</fpage><?supplied-pmid 26964063?><pub-id pub-id-type="pmid">26964063</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lood</surname><given-names>R</given-names></name><name><surname>Morgelin</surname><given-names>M</given-names></name><name><surname>Holmberg</surname><given-names>A</given-names></name><name><surname>Rasmussen</surname><given-names>M</given-names></name><name><surname>Collin</surname><given-names>M</given-names></name></person-group><article-title>Inducible siphoviruses in superficial and deep tissue isolates of <italic>Propionibacterium acnes</italic></article-title><source>BMC Microbiol</source><year>2008</year><volume>8</volume><fpage>139</fpage><?supplied-pmid 18702830?><pub-id pub-id-type="pmid">18702830</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zierdt</surname><given-names>CH</given-names></name></person-group><article-title>Properties of <italic>Corynebacterium acnes</italic> bacteriophage and description of an interference phenomenon</article-title><source>J Virol</source><year>1974</year><volume>14</volume><issue>5</issue><fpage>1268</fpage><lpage>1273</lpage><?supplied-pmid 4431080?><pub-id pub-id-type="pmid">4431080</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruttin</surname><given-names>A</given-names></name><name><surname>Brussow</surname><given-names>H</given-names></name></person-group><article-title>Human volunteers receiving <italic>Escherichia coli</italic> phage T4 orally: a safety test of phage therapy</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><issue>7</issue><fpage>2874</fpage><lpage>2878</lpage><?supplied-pmid 15980363?><pub-id pub-id-type="pmid">15980363</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutter</surname><given-names>E</given-names></name><name><surname>De Vos</surname><given-names>D</given-names></name><name><surname>Gvasalia</surname><given-names>G</given-names></name><etal/></person-group><article-title>Phage therapy in clinical practice: treatment of human infections</article-title><source>Curr Pharm Biotechnol</source><year>2010</year><volume>11</volume><issue>1</issue><fpage>69</fpage><lpage>86</lpage><?supplied-pmid 20214609?><pub-id pub-id-type="pmid">20214609</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhoads</surname><given-names>DD</given-names></name><name><surname>Wolcott</surname><given-names>RD</given-names></name><name><surname>Kuskowski</surname><given-names>MA</given-names></name><name><surname>Wolcott</surname><given-names>BM</given-names></name><name><surname>Ward</surname><given-names>LS</given-names></name><name><surname>Sulakvelidze</surname><given-names>A</given-names></name></person-group><article-title>Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial</article-title><source>J Wound Care</source><year>2009</year><volume>18</volume><issue>6</issue><fpage>237</fpage><lpage>238</lpage><?supplied-pmid 19661847?><pub-id pub-id-type="pmid">19661847</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>A</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name><name><surname>Angg&#x000e5;rd</surname><given-names>E</given-names></name><name><surname>Harper</surname><given-names>D</given-names></name></person-group><article-title>A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant <italic>Pseudomonas aeruginosa</italic>; a preliminary report of efficacy</article-title><source>Clin Otolaryngol</source><year>2009</year><volume>34</volume><issue>4</issue><fpage>349</fpage><lpage>357</lpage><?supplied-pmid 19673983?><pub-id pub-id-type="pmid">19673983</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="other">Neely K, Albright B, Zurowski M, Davis M. Development of bacteriophage therapy for the skin disease acne. In: The 108th General Meeting of the American Society for Microbiology. Boston; 2008.</mixed-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Flaherty</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name><name><surname>Meaney</surname><given-names>W</given-names></name><name><surname>Fitzgerald</surname><given-names>G</given-names></name><name><surname>Elbreki</surname><given-names>M</given-names></name><name><surname>Coffey</surname><given-names>A</given-names></name></person-group><article-title>Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci fromhospitals</article-title><source>Appl Environ Microbiol</source><year>2005</year><volume>71</volume><fpage>1836</fpage><lpage>1842</lpage><?supplied-pmid 15812009?><pub-id pub-id-type="pmid">15812009</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmelcher</surname><given-names>M</given-names></name><name><surname>Donovan</surname><given-names>D</given-names></name><name><surname>Loessner</surname><given-names>M</given-names></name></person-group><article-title>Bacteriophage endolysins as novel antimicrobials</article-title><source>Future Microbiol</source><year>2012</year><volume>7</volume><issue>10</issue><fpage>1147</fpage><lpage>1171</lpage><?supplied-pmid 23030422?><pub-id pub-id-type="pmid">23030422</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>D</given-names></name><name><surname>Schmelcher</surname><given-names>M</given-names></name><name><surname>Rodriguez-Rubio</surname><given-names>L</given-names></name><etal/></person-group><article-title>Endolysins as antimicrobials</article-title><source>Adv Virus Res</source><year>2012</year><volume>83</volume><fpage>299</fpage><?supplied-pmid 22748813?><pub-id pub-id-type="pmid">22748813</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loc-Carrillo</surname><given-names>C</given-names></name><name><surname>Abedon</surname><given-names>ST</given-names></name></person-group><article-title>Pros and cons of phage therapy</article-title><source>Bacteriophage</source><year>2011</year><volume>1</volume><issue>2</issue><fpage>111</fpage><lpage>114</lpage><?supplied-pmid 22334867?><pub-id pub-id-type="pmid">22334867</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>S</given-names></name><name><surname>Yasuda</surname><given-names>M</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Experimental protection of mice against lethal <italic>Staphylococcus aureus</italic> infection by novel bacteriophage phi MR11</article-title><source>J Infect Dis</source><year>2003</year><volume>187</volume><issue>4</issue><fpage>613</fpage><lpage>624</lpage><?supplied-pmid 12599078?><pub-id pub-id-type="pmid">12599078</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>B</given-names></name><name><surname>Adhya</surname><given-names>S</given-names></name><name><surname>Washart</surname><given-names>P</given-names></name><etal/></person-group><article-title>Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant <italic>Enterococcus faecium</italic></article-title><source>Infect Immun</source><year>2002</year><volume>70</volume><issue>1</issue><fpage>204</fpage><lpage>210</lpage><?supplied-pmid 11748184?><pub-id pub-id-type="pmid">11748184</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinodkumar</surname><given-names>CS</given-names></name><name><surname>Neelagund</surname><given-names>YF</given-names></name><name><surname>Kalsurmath</surname><given-names>S</given-names></name></person-group><article-title>Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant <italic>Klebsiella pneumoniae</italic></article-title><source>J Commun Dis</source><year>2005</year><volume>37</volume><issue>1</issue><fpage>18</fpage><lpage>29</lpage><?supplied-pmid 16637396?><pub-id pub-id-type="pmid">16637396</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant <italic>Pseudomonas aeruginosa</italic></article-title><source>Int J Mol Med</source><year>2006</year><volume>17</volume><fpage>309</fpage><lpage>317</lpage><?supplied-pmid 16391831?><pub-id pub-id-type="pmid">16391831</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing <italic>Escherichia coli</italic> bacteremia</article-title><source>Int J Mol Med</source><year>2006</year><volume>17</volume><issue>2</issue><fpage>347</fpage><lpage>355</lpage><?supplied-pmid 16391836?><pub-id pub-id-type="pmid">16391836</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chibani-Chennoufi</surname><given-names>S</given-names></name><name><surname>Sidoti</surname><given-names>J</given-names></name><name><surname>Bruttin</surname><given-names>A</given-names></name><name><surname>Kutter</surname><given-names>E</given-names></name><name><surname>Sarker</surname><given-names>S</given-names></name><name><surname>Brussow</surname><given-names>H</given-names></name></person-group><article-title>In vitro and in vivo bacteriolytic activities of <italic>Escherichia coli</italic> phages: implications for phage therapy</article-title><source>Antimicrob Agents Chemother</source><year>2004</year><volume>48</volume><issue>7</issue><fpage>2558</fpage><lpage>2569</lpage><?supplied-pmid 15215109?><pub-id pub-id-type="pmid">15215109</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merabishvili</surname><given-names>M</given-names></name><name><surname>De Vos</surname><given-names>D</given-names></name><name><surname>Verbeken</surname><given-names>G</given-names></name><etal/></person-group><article-title>Selection and characterization of a candidate therapeutic bacteriophage that lyses the <italic>Escherichia coli</italic> O104:H4 strain from the 2011 outbreak in Germany</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e52709</fpage><?supplied-pmid 23285164?><pub-id pub-id-type="pmid">23285164</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouillot</surname><given-names>F</given-names></name><name><surname>Chomton</surname><given-names>M</given-names></name><name><surname>Blois</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 <italic>Escherichia coli</italic> strain producing CTX-M-15</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><issue>7</issue><fpage>3568</fpage><lpage>3575</lpage><?supplied-pmid 22491690?><pub-id pub-id-type="pmid">22491690</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chhibber</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>T</given-names></name><name><surname>Sandeep</surname><given-names>K</given-names></name></person-group><article-title>Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant <italic>Staphylococcus aureus</italic> (MRSA) from diabetic foot infections</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>2</issue><fpage>e56022</fpage><?supplied-pmid 23418497?><pub-id pub-id-type="pmid">23418497</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golkar</surname><given-names>Z</given-names></name><name><surname>Bagasra</surname><given-names>O</given-names></name><name><surname>Pace</surname><given-names>DG</given-names></name></person-group><article-title>Bacteriophage therapy: a potential solution for the antibiotic resistance crisis</article-title><source>J Infect Dev Ctries</source><year>2014</year><volume>8</volume><issue>2</issue><fpage>129</fpage><lpage>136</lpage><?supplied-pmid 24518621?><pub-id pub-id-type="pmid">24518621</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarker</surname><given-names>SA</given-names></name><name><surname>McCallin</surname><given-names>S</given-names></name><name><surname>Barretto</surname><given-names>C</given-names></name><etal/></person-group><article-title>Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh</article-title><source>Virology</source><year>2012</year><volume>434</volume><issue>2</issue><fpage>222</fpage><lpage>232</lpage><?supplied-pmid 23102968?><pub-id pub-id-type="pmid">23102968</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorski</surname><given-names>A</given-names></name><name><surname>Miedzybrodzki</surname><given-names>R</given-names></name><name><surname>Borysowski</surname><given-names>J</given-names></name><etal/></person-group><article-title>Bacteriophage therapy for the treatment of infections</article-title><source>Curr Opin Investig Drugs</source><year>2009</year><volume>10</volume><issue>8</issue><fpage>766</fpage><lpage>774</lpage><?supplied-pmid 19649921?><pub-id pub-id-type="pmid">19649921</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azeredo</surname><given-names>J</given-names></name><name><surname>Sutherland</surname><given-names>I</given-names></name></person-group><article-title>The use of phages for the removal of infectious biofilm</article-title><source>Curr Pharm Biotechnol</source><year>2008</year><volume>9</volume><fpage>261</fpage><lpage>266</lpage><?supplied-pmid 18691087?><pub-id pub-id-type="pmid">18691087</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alemayehu</surname><given-names>D</given-names></name><name><surname>Casey</surname><given-names>P</given-names></name><name><surname>McAuliffe</surname><given-names>O</given-names></name><etal/></person-group><article-title>Bacteriophages &#x003d5;MR299-2 and &#x003d5;NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells</article-title><source>mBio</source><year>2012</year><volume>3</volume><issue>2</issue><fpage>e00029</fpage><?supplied-pmid 22396480?><pub-id pub-id-type="pmid">22396480</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alves</surname><given-names>DR</given-names></name><name><surname>Perez-Esteban</surname><given-names>P</given-names></name><name><surname>Kot</surname><given-names>W</given-names></name><etal/></person-group><article-title>A novel bacteriophage cocktail reduces and disperses <italic>Pseudomonas aeruginosa</italic> biofilms under static and flow conditions</article-title><source>Microb Biotechnol</source><year>2016</year><volume>9</volume><issue>1</issue><fpage>61</fpage><lpage>74</lpage><?supplied-pmid 26347362?><pub-id pub-id-type="pmid">26347362</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtin</surname><given-names>J</given-names></name><name><surname>Donlanm</surname><given-names>R</given-names></name></person-group><article-title>Using bacteriophages to reduce formation of catheter-associated biofilms by <italic>Staphylococcus epidermidis</italic></article-title><source>Antimicrob Agents Chemother</source><year>2006</year><volume>50</volume><issue>4</issue><fpage>1268</fpage><lpage>1275</lpage><?supplied-pmid 16569839?><pub-id pub-id-type="pmid">16569839</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>SA</given-names></name><name><surname>Drilling</surname><given-names>A</given-names></name><name><surname>Morales</surname><given-names>S</given-names></name><etal/></person-group><article-title>Activity of bacteriophages in removing biofilms of <italic>Pseudomonas aeruginosa</italic> isolates from chronic rhinosinusitis patients</article-title><source>Front Cell Infect Microbiol</source><year>2017</year><volume>7</volume><fpage>418</fpage><?supplied-pmid 29018773?><pub-id pub-id-type="pmid">29018773</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehman</surname><given-names>SM</given-names></name><name><surname>Donlan</surname><given-names>RM</given-names></name></person-group><article-title>Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model</article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><issue>2</issue><fpage>1127</fpage><lpage>1137</lpage><?supplied-pmid 25487795?><pub-id pub-id-type="pmid">25487795</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comeau</surname><given-names>AM</given-names></name><name><surname>T&#x000e9;tart</surname><given-names>F</given-names></name><name><surname>Trojet</surname><given-names>S</given-names></name><name><surname>Pr&#x000e8;re</surname><given-names>M</given-names></name><name><surname>Krisch</surname><given-names>H</given-names></name></person-group><article-title>Phage&#x02013;antibiotic synergy (PAS): blactam and quinolone antibiotics stimulate virulent phage growth</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><fpage>e799</fpage><?supplied-pmid 17726529?><pub-id pub-id-type="pmid">17726529</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulter</surname><given-names>LB</given-names></name><name><surname>McLean</surname><given-names>RJ</given-names></name><name><surname>Rohde</surname><given-names>RE</given-names></name><name><surname>Aron</surname><given-names>GM</given-names></name></person-group><article-title>Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in <italic>Escherichia coli</italic> and <italic>Pseudomonas aeruginosa</italic> biofilms</article-title><source>Viruses</source><year>2014</year><volume>6</volume><issue>10</issue><fpage>3778</fpage><lpage>3786</lpage><?supplied-pmid 25285538?><pub-id pub-id-type="pmid">25285538</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagens</surname><given-names>S</given-names></name><name><surname>Habel</surname><given-names>A</given-names></name><name><surname>Blasi</surname><given-names>U</given-names></name></person-group><article-title>Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage</article-title><source>Microbial Drug Resist (Larchmt, NY)</source><year>2006</year><volume>12</volume><issue>3</issue><fpage>164</fpage><lpage>168</lpage></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamal</surname><given-names>F</given-names></name><name><surname>Dennis</surname><given-names>JJ</given-names></name></person-group><article-title>Burkholderia cepacia complex phage-antibiotic synergy (PAS): antibiotics stimulate lytic phage activity</article-title><source>Appl Environ Microbiol</source><year>2015</year><volume>81</volume><issue>3</issue><fpage>1132</fpage><lpage>1138</lpage><?supplied-pmid 25452284?><pub-id pub-id-type="pmid">25452284</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>AE</given-names></name></person-group><article-title>Synergistic action of gentamicin and bacteriophage in a continuous culture population of <italic>Staphylococcus aureus</italic></article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>11</issue><fpage>e51017</fpage><?supplied-pmid 23226451?><pub-id pub-id-type="pmid">23226451</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knezevic</surname><given-names>P</given-names></name><name><surname>Curcin</surname><given-names>S</given-names></name><name><surname>Aleksic</surname><given-names>V</given-names></name><name><surname>Petrusic</surname><given-names>M</given-names></name><name><surname>Vlaski</surname><given-names>L</given-names></name></person-group><article-title>Phage-antibiotic synergism: a possible approach to combatting <italic>Pseudomonas aeruginosa</italic></article-title><source>Res Microbiol</source><year>2013</year><volume>164</volume><issue>1</issue><fpage>55</fpage><lpage>60</lpage><?supplied-pmid 23000091?><pub-id pub-id-type="pmid">23000091</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Barcelo</surname><given-names>C</given-names></name><name><surname>Arias-Sanchez</surname><given-names>FI</given-names></name><name><surname>Vasse</surname><given-names>M</given-names></name><name><surname>Ramsayer</surname><given-names>J</given-names></name><name><surname>Kaltz</surname><given-names>O</given-names></name><name><surname>Hochberg</surname><given-names>ME</given-names></name></person-group><article-title>A window of opportunity to control the bacterial pathogen <italic>Pseudomonas aeruginosa</italic> combining antibiotics and phages</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>9</issue><fpage>e106628</fpage><?supplied-pmid 25259735?><pub-id pub-id-type="pmid">25259735</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Barcel&#x000f3;</surname><given-names>C</given-names></name><name><surname>Hochberg</surname><given-names>M</given-names></name></person-group><article-title>Evolutionary rationale for phages as complements of antibiotics</article-title><source>Trends Microbiol</source><year>2016</year><volume>24</volume><issue>4</issue><fpage>249</fpage><lpage>256</lpage><?supplied-pmid 26786863?><pub-id pub-id-type="pmid">26786863</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>V</given-names></name><name><surname>Harjai</surname><given-names>K</given-names></name><name><surname>Chhibber</surname><given-names>S</given-names></name></person-group><article-title>Restricting ciprofloxacin-induced resistant variant formation in biofilm of <italic>Klebsiella pneumoniae</italic> B5055 by complementary bacteriophage treatment</article-title><source>J Antimicrob Chemother</source><year>2009</year><volume>64</volume><issue>6</issue><fpage>1212</fpage><lpage>1218</lpage><?supplied-pmid 19808232?><pub-id pub-id-type="pmid">19808232</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>QG</given-names></name><name><surname>Buckling</surname><given-names>A</given-names></name></person-group><article-title>Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms</article-title><source>Evol Appl</source><year>2012</year><volume>5</volume><issue>6</issue><fpage>575</fpage><lpage>582</lpage><?supplied-pmid 23028398?><pub-id pub-id-type="pmid">23028398</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miedzybrodzki</surname><given-names>R</given-names></name><name><surname>Fortuna</surname><given-names>W</given-names></name><name><surname>Weber-Dabrowska</surname><given-names>B</given-names></name><name><surname>G&#x000f3;rski</surname><given-names>A</given-names></name></person-group><article-title>Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment</article-title><source>Postepy Hig Med Dosw</source><year>2007</year><volume>3</volume><fpage>461</fpage><lpage>465</lpage></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denou</surname><given-names>E</given-names></name><name><surname>Bruttin</surname><given-names>A</given-names></name><name><surname>Barretto</surname><given-names>C</given-names></name><name><surname>Ngom-Bru</surname><given-names>C</given-names></name><name><surname>Brussow</surname><given-names>H</given-names></name><name><surname>Zuber</surname><given-names>S</given-names></name></person-group><article-title>T4 phages against <italic>Escherichia coli</italic> diarrhea: potential and problems</article-title><source>Virology</source><year>2009</year><volume>388</volume><issue>1</issue><fpage>21</fpage><lpage>30</lpage><?supplied-pmid 19339031?><pub-id pub-id-type="pmid">19339031</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miedzybrodzki</surname><given-names>R</given-names></name><name><surname>Borysowski</surname><given-names>J</given-names></name><name><surname>Weber-Dabrowska</surname><given-names>B</given-names></name><etal/></person-group><article-title>Clinical aspects of phage therapy</article-title><source>Adv Virus Res</source><year>2012</year><volume>83</volume><fpage>73</fpage><lpage>121</lpage><?supplied-pmid 22748809?><pub-id pub-id-type="pmid">22748809</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DM</given-names></name><name><surname>Koskella</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name></person-group><article-title>Phage therapy: an alternative to antibiotics in the age of multi-drug resistance</article-title><source>World J Gastrointest Pharmacol Ther</source><year>2017</year><volume>8</volume><issue>3</issue><fpage>162</fpage><lpage>173</lpage><?supplied-pmid 28828194?><pub-id pub-id-type="pmid">28828194</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drulis-Kawa</surname><given-names>Z</given-names></name><name><surname>Majkowska-Skrobek</surname><given-names>G</given-names></name><name><surname>Maciejewska</surname><given-names>B</given-names></name><name><surname>Delattre</surname><given-names>AS</given-names></name><name><surname>Lavigne</surname><given-names>R</given-names></name></person-group><article-title>Learning from bacteriophages&#x02014;advantages and limitations of phage and phage-encoded protein applications</article-title><source>Curr Protein Pept Sci</source><year>2012</year><volume>13</volume><issue>8</issue><fpage>699</fpage><lpage>722</lpage><?supplied-pmid 23305359?><pub-id pub-id-type="pmid">23305359</pub-id></element-citation></ref></ref-list></back></article>